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Objectives:In the present study, we investigated whether the pH of IP6 could inﬂuence its
anti-tumoral activity in vitro. Methods:PC-3 cells were exposed to IP6 at pH 5, pH 7 , and pH
12 and we evaluated the metabolic activity (WST-1 assay), cell proliferation (cell count), cell
cycle distribution (FACS), and mitochondrial depolarization (JC-1 staining) in vitro. Results:
Our results demonstrated that IP6 at pH 5 and pH 12 were more potent at lowering the
metabolic activity of PC-3 cells than IP6 at pH 7 .Treatment with IP6 at pH 12 also caused
the greatest inhibition in cellular proliferation and accumulation of PC-3 cells in sub-G1.
Finally, IP6 at pH 12 lead to a reduction in phospho-AKT and phospho-PDK1 and upregu-
lated phospho-ERK. Conclusion: Together, our data strongly suggest that the pH of IP6
effectively modulates its anti-tumoral activity and should be reported in future studies.
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INTRODUCTION
Inositol hexakisphosphate (IP6) is a phytochemical that exhibits
promising anti-tumoral properties against several mouse,rat,and
human cancer cell lines including prostate cancer cells (Vucenik
and Shamsuddin, 2006). IP6 is present in most cereals, legumes,
nuts, oil seed, and soybean (Shamsuddin et al., 1997; Jariwalla,
2001) and is available as an over-the-counter dietary supplement
without any reported toxicity or adverse reactions (Vucenik and
Shamsuddin, 2003).
Effects on tumor cell proliferation, survival, and angiogene-
sis, were documented as being key anti-tumoral properties of
IP6 against prostate cancer cells. Initial studies in PC-3 cells
demonstrated that IP6 inhibits the growth and promotes the dif-
ferentiation of PC-3 cells (Shamsuddin and Yang, 1995). Both
hormone-sensitive (LNCaP) and hormone-refractory (Du145)
cellsaresensitivetoG1cellcyclearrestandapoptosiscausedbyIP6
(Singh et al., 2003; Agarwal et al., 2004). Our group later showed
that hormone-refractory prostate cancer cells (DU145 and PC-3
cells)weremoresensitivetoIP6treatmentthanhormone-sensitive
prostate cancer cells (LNCaP and 22rv1 cells; Diallo et al.,2006).
In prostate cancer mice models, IP6 has documented in vivo
anti-tumoral activity (Raina et al.,2008; Gu et al.,2009). Athymic
mice,whosedrinkingwaterwassupplementedwithIP6,exhibited
reduced growth of DU145 xenografts, which was associated with
diminished tumor cell proliferation, increased tumor cell apop-
tosis, and reduced angiogenesis (Singh et al., 2004). In transgenic
adenocarcinoma of the mouse prostate (TRAMP) mice, IP6 sup-
plementationcausesthedevelopmentofasmallerlowerurogenital
track (bladder, seminal vesicles, prostate), an increase incidence
of prostate intraepithelial neoplasia (PIN; low-grade and high-
grade),andadecreasedincidenceof adenocarcinoma(Rainaetal.,
2008).
In terms of intracellular signaling,IP6 affects several pathways.
IP6 decreases phospho-AKT (S473) in DU145 cells (Jagadeesh
and Banerjee, 2006). In PC-3 cells, where PI3K signaling is
constitutively activated due to altered expression/functions of
PTEN, IP6 reduces phosphorylation of PI3K p85 (Y458), 3-
phosphoinositide-dependent kinase 1 (PDK1; S241), AKT (S473
and T208), GSK3α/β (S21 and S9), decreases ILK1, and cyclin D1
p r o t e i nl e v e l s( Gu et al., 2009). Altogether, IP6 shows promising
cytotoxicactivityagainsthormone-refractoryprostatecancercells
such as DU145 and PC-3.
As IP6 is generally administered orally through the diet,
typically in drinking water, IP6 must be buffered to a neu-
tral pH before ingestion. IP6 salts are commercially available
in several forms, which when reconstituted in water result in
widely different pH. Typical formulations of the IP6 salt are
basic and when reconstituted in water result in a solution at
pH 12, which is not apt for consumption. The goal of this
study was thus to validate whether the previously documented
anti-tumoral properties of IP6 were modulated by the pH. Our
results demonstrate that IP6 at pH 12 had different effects
than IP6 solutions at pH 7 or pH 5. We conclude that the
effect of pH should be carefully monitored when evaluating the
cytotoxic and anti-cancer properties of IP6 and possibly other
phytochemicals.
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MATERIALS AND METHODS
CELL CULTURE AND REAGENTS
PC-3 and LNCaP cells were obtained from ATCC (Rockville,MD,
USA). Myo-Inositol hexakisphosphate dodecasodium salt (IP6;
US Biological, Swampscott, MA, USA) was diluted in water as
a 100-mM stock solution. The IP6 stock solution was at pH
12. The pH was adjusted to pH 5 or pH 7 by addition of 1N
hydrochloric acid (HCl). It required 6.4 and 10.9ml of 1N HCl
to buffer 100ml of 100mM IP6 pH 12 to pH 7 and pH 5, respec-
tively. Antibodies recognizing phospho-AKT (S473; cat# 9271),
phospho-PDK1(S241;3438)andphospho-ERK(T202/Y204;cat#
9106L) were obtained from Cell Signaling (Danvers, MA, USA).
Antibodies detecting PARP full-length (sc7150), PARP 85kDa
(cat# 9541), PARP 25kDa (cat# 32064) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), Cell Signaling and
Abcam (Cambridge, MA, USA), respectively. The anti-Ran anti-
body (sc1146) and the horseradish peroxidase-conjugated sec-
ondary antibodies were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). The antibodies recognizing actin
(ab-6278) and GAPDH (ab-9485) were obtained from Abcam
(Cambridge, MA, USA).
WST-1 METABOLIC ASSAY
The WST-1 metabolic assay was done as previously described by
our group (Diallo et al., 2006, 2008). Brieﬂy, PC-3 cells were
plated at 200,000 cells/ml in 96-well plates in a ﬁnal volume of
100μl/well.Aftera24-hincubationwithH2OorIP6atthevarious
pH and at the indicated concentrations, 20μl of WST-1 reagent
(Roche Diagnostics, Indianapolis, IN, USA) was added and the
plates were incubated for 24h. WST-1 signal was measured at
450nm with reference wavelength at 655nm.
CELLULAR PROLIFERATION
PC-3 cells were plated at 15,000 cells/ml in 6-well plates, allowed
to adhere overnight and then treated with 2mM IP6 at pH 5,
pH 7, or pH 12 or the equivalent volumes of pH-adjusted H2O
controls over a period of 72h. At indicated times cells were
trypsinized,combinedwithnon-adherentcellsandcountedusing
a cell counter (Casy,Roche Innovatis,Germany).
CELL CYCLE DISTRIBUTION ANALYSIS
PC-3 cells were plated at 200,000 cells/ml in 6-well plates. PC-3
c e l l sw e r ee x p o s e dt oH 2O or 2mM IP6 at the various pH for 8,
24, 48, and 72h. Adherent cells were trypsinized, combined with
non-adherent cells, stained with propidium iodide (PI), and ana-
lyzed by ﬂow cytometry. All experiments were repeated at least
three times.
WESTERN BLOT ANALYSIS
Western blots were performed as previously described by our
group (Diallo et al., 2006, 2008). Signal was developed with
enhanced chemiluminescence (ECL) substrate (Amersham Life
Sciences Inc.,Arlington Heights, IL, USA).
MITOCHONDRIAL DEPOLARIZATION ASSAY
The mitochondrial assay was done as previously described by our
group(Dialloetal.,2008).Brieﬂy,PC-3cellswereplatedat200,000
cells/ml in 6-well plates. PC-3 cells were incubated with a ﬂuores-
cent cationic dye (JC-1 10μg/ml) for 15min. Adherent cells were
trypsinized, combined with non-adherent cells, and analyzed by
ﬂow cytometry. The fold change representing depolarized mito-
chondria (green-shift in JC-1 ﬂuorescence) was calculated relative
to mock-treated control.
STATISTICAL ANALYSES
Data are expressed as mean±SD. Comparisons between the IP6
or H2O controls at the various pH were performed using one-way
ANOVA followed by post hoc Tukey tests. Statistical analyses were
performedusingSPSSversion16.0(SPSS,Inc.,Chicago,IL,USA).
For all statistical analyses, P values <0.05 were considered to be
statistically signiﬁcant.
RESULTS
IP6 DIMINISHES THE METABOLIC ACTIVITY OF PC-3 CELLS
We ﬁrst evaluated the effect of the pH of IP6 on the metabolic
activity of PC-3 cells. The cells were treated with either increasing
doses of IP6 at pH 5, pH 7, and pH 12 or the corresponding vol-
umes of H2O also at pH 5, pH 7, and pH 12. IP6 at pH 5 (2.5, 4,
and 5mM) and pH 12 (4 and 5mM) induced a statistically signif-
icant reduction in the metabolic activity of PC-3 cells (Figure1A)
compared to the buffered H2O( Figure 1B; P <0.05, ANOVA).
Statistically signiﬁcant differences compared to the H2O controls
were not observed with IP6 at pH 7,independently of the concen-
tration tested. With regards to pH, the IP6 at pH 12 and at pH 5
had the strongest inhibitory potential. At the highest doses tested,
IP6 at pH 5 reduced the metabolic rate by 88.0% (P<0.001,com-
pared to H2O at pH 5, ANOVA), and, at similar concentration,
IP6 at pH 12 decreased the metabolic rate by 78.6% (P<0.001,
compared to H2O at pH 12,ANOVA). Comparatively,the highest
dose of IP6 solution at pH 7 only reduced the metabolic activity
by 26.1% (P=0.627,compared to H2O at pH 7,ANOVA). More-
over, the lowest concentration at which IP6 at pH 5 and pH 12
statistically signiﬁcantly reduced the metabolic rate was 2.5mM
(P=0.001, compared to H2Oa tp H5a n dP =0.012, compared
to H2O at pH 12,respectively,ANOVA).
We then evaluated the IC50 and IC75 for the various IP6 solu-
tions.Duetotheabsenceofasigniﬁcantreductioninthemetabolic
activity following treatment with IP6 at pH 7 no IC50 could be
calculated. The IC50 for IP6 at pH 5 was 2.39±0.19mM and
2.97±0.45 for IP6 at pH 12 (Table 1). Together, these results
demonstrate that IP6 solutions at different pH have divergent
effect on the metabolic activity of PC-3 cells.
Finally, we inquired whether the addition of small volumes
(60μl)ofIP6orbufferedH2Osolutionscouldsigniﬁcantlychange
the pH of the culture media (FigureA1 in Appendix). Our analy-
ses showed that,at time of administration (t – 0h) and compared
to water controls,the IP6 at pH 12 and at pH 5 signiﬁcantly mod-
ulated the pH of the culture media (P <0.001, ANOVA). These
changes in pH were however absent after 24h of treatment.
IP6 AT pH 12 HAS THE STRONGEST ANTI-PROLIFERATION EFFECT ON
PC-3 CELLS
We next evaluated the impact of pH on the anti-proliferation
action of IP6. As previously described, PC-3 cells were treated
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FIGURE 1 | IP6 decreases the metabolic activity and cellular
proliferation of PC-3 cell lines. (A,B) PC-3 cells were treated for 24h with
increasing concentration of (A) IP6 at pH 5, pH 7 , or pH 12 or (B)
corresponding volume of H2O at pH 5, pH 7 , or pH 12. Metabolic activity was
measured using the WST-1 assay and calculated relative to controls. Data
represents the average of three experiments done in triplicate. Errors bars
represent standard error of the mean. Statistically signiﬁcant differences
compared to the corresponding water control. (C,D) PC-3 cells were treated
with (C) 2mM IP6 at pH 5, pH 7 , or pH 12 or (D) the corresponding volumes
of H2O at pH 5, pH 7 , and pH 12. Cellular proliferation was examined by cell
count at 24, 48, and 72h. Data represents average of three experiments.
Errors bars represent standard error of the mean. Statistically signiﬁcant
differences compared to the corresponding water control where *P<0.05
and **P <0.001 (ANOVA).
with 2mM IP6 solutions or with the corresponding volumes of
buffered H2O. We chose the 2-mM IP6 dose in line with other
studies by our group (Diallo et al., 2008) and others (Gu et al.,
2009; Roy et al., 2009). Following a 72-h stimulation, IP6 at pH
12 signiﬁcantly reduced cell number by 60.4% (P =0.001, com-
pared to H2O at pH 12,ANOVA),whereas a treatment with IP6 at
pH 5 reduced the proliferation rate by 46.9% (P =0.0029, com-
pared to H2O at pH 5, ANOVA), and by 46.6% for the IP6 at pH
7( P =0.015,compared to H2Oa tp H7 ,A N O V A ;Figures 1C,D).
Together, these results suggest that IP6 at pH 12 had the strongest
anti-proliferation potential.
IP6 AT pH 12 INCREASES THE PROPORTION OF SUB-G1 PC-3 CELLS
We then assessed whether the reduction in metabolic activity and
in cellular proliferation (Figure 1) was related to an increase in
cell death. PC-3 cells were treated as previously described with
either 2mM IP6 or H2O controls over a period of 72h. Adherent
and non-adherent cells were analyzed by FACS,following staining
with PI for 15min. We observed that, compared to H2O, only the
T a b l e1|I C 50 and IC75 of IP6 at varying pH.
[] at *IC50 [] at *IC75
IP6 pH 5 2.39±0.19 3.96±0.60
IP6 pH 7 N/A N/A
IP6 pH 12 2.97±0.45 4.04±0.64
N/A, non-applicable.
*Concentration in millimolar.
IP6 solution at pH 12 caused a statistically signiﬁcant increase in
sub-G1 cells at 8h (5.21 vs 0.71%,P <0.001,ANOVA) and at 24h
(3.96vs0.59%,P <0.001,ANOVA;Figure2A).At8h,theincrease
in sub-G1 cells was also associated with a decrease in PC-3 cells
in G2/M phase (Table 2). No statistically signiﬁcant induction of
sub-G1 PC-3 cells were observed following treatment with IP6 at
pH5oratpH7orwiththecorrespondingH2Ocontrols(Table A1
in Appendix).
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FIGURE 2 | IP6 at pH 12 leads to an increase in sub-G1 PC-3 cells.
(A) PC-3 cells were stained with PI after a 24-h treatment with either
2mM IP6 at pH 5, pH 7 , or pH 12 or the corresponding volumes of
H2O at pH 5, pH 7 , and pH 12.The percentage of cells in G1, S, G2/M, and
sub-G1 phases was determined by FACS. MG132 served as a control to
induce cellular apoptosis. Data is represented as the relative fold change
compared to non-treated control. Average of three experiments done in
triplicate. Errors bars represent standard error of the mean. (B) Whole-cell
extracts were prepared following a 24-h treatment as previously described.
Western blotting was used to probe for PARP and cleaved-PARP (85 and
25kDa). RAN expression was used as a loading control. Blot is representative
of three independent experiments.
IP6 AT pH 12 MODULATES THE LEVEL OF PARP-1
By Western blot, we then studied whether Poly (ADP-ribose)
polymerase 1 (PARP-1), was cleaved following IP6 treatment, as
an indication of apoptosis induction. Following a 24-h stimu-
lation with 2mM IP6 at pH 12, we observed a most complete
disappearance of full-length PARP-1 (Figure 2B). Surprisingly,
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this reduction in PARP-1 expression was not associated with the
appearance of the cleaved-PARP 85 and 25kDa fragments as
observed with the MG132 positive control stimulation. We did
notdetectanyreducedexpressionoffull-lengthPARP-1orPARP-1
cleavage following treatment with IP6 at pH 5 or at pH 7.
We also noticed that the effects observed by IP6 at different
pH varied according to the cell line used in the experiment.
Using the hormone-sensitive LNCaP cell line treated with the
various IP6 solutions, we observed an elevated expression of
the cleaved-PARP-1 25kDa fragment following exposure to IP6,
somethingthatwasnotobservedwiththePC-3cellline(FigureA2
in Appendix).
IP6 DOES NOT CAUSE MITOCHONDRIAL DEPOLARIZATION
The reduction in metabolic activity, cellular proliferation com-
bined with the abundance of sub-G1 PC-3 cells lead us to
Table 2 | Cell cycle distribution* after 8h of IP6 treatment.
G1 S G2/M Sub-G1
Ctrl 53.56±2.01 9.23±1.43 25.96±0.86 0.51±0.09
MG132 54.10±2.55 7 .86±1.13 27 .76±4.33 0.59±0.08
H2O pH 5 53.18±2.15 11.00±2.60 25.67±1.33 0.45±0.09
H2O pH 7 53.53±1.91 11.23±2.78 25.72±1.39 0.41±0.08
H2O pH 12 53.15±2.53 10.10±1.75 25.72±1.31 0.71±0.25
IP6 pH 5 53.95±1.85 10.88±2.70 25.80±0.86 0.61±0.10
IP6 pH 7 53.63±2.62 10.41±1.48 26.03±0.58 0.68±0.13
IP6 pH 12 50.24±3.25 8.85±1.80 22.13±0.97 5.21±0.88
Results highlighted and in bold are statistically signiﬁcantly different.
Compared to the corresponding water control.
*Cell percentage in each phase quantiﬁed by FACS following PI staining.
FIGURE 3 | IP6 does not impact mitochondrial depolarization. PC-3 cells
were treated with either 2mM IP6 at pH 5, pH 7 , or pH 12 or the
corresponding volumes of H2O at pH 5, pH 7 , and pH 12 for after 4, 8, 24, and
48h. In the last 15min prior to analysis, cells were stained with JC-1 and
mitochondrial depolarization was assessed by FACS. MG132 served as a
control to induce cellular apoptosis. Data is represented as the relative fold
change compared to non-treated control. Average of three experiments done
in triplicate. Errors bars represent standard error of the mean.
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investigate mitochondrial depolarization or mitochondrial outer
membrane permeation (MOMP), another event associate with
apoptotic cell death. Similar to PARP cleavage (Kaufmann et al.,
1993),mitochondrialdepolarizationisanearlyeventof apoptosis,
which is associated with the release of cytochrome c (Heiskanen
et al., 1999). Mitochondrial depolarization can be quantiﬁed by a
shift from red to green following JC-1 staining. Our results illus-
trate that, compared to H2O controls, there was no statistically
signiﬁcant induction of mitochondrial depolarization by IP6 at
the various pH studied (Figure 3). Together, these results suggest
that IP6 promotes the accumulation of sub-G1 PC-3 cells and the
reducedexpressionofPARP.However,thisincreaseinsub-G1cells
was not associated with the appearance of cleaved-PARP or mito-
chondrial depolarization, two factors typically associated with an
apoptotic cell death.
IP6 AT pH 12 MODULATES INTRACELLULAR SIGNALIZATION
Finally, we then evaluated whether the pH of the IP6 solution
could differentially affect the phosphorylation status of intracel-
lular effectors documented to be modulated by IP6. We detected
a clear decrease in the phosphorylation status of AKT (S473) and
PDK1 (S241) following treatment with IP6 at pH 12 (Figure 4A).
Again, these variations were not observed with the IP6 at pH 5
or at pH 7. Conversely, we observed an induced expression of
phospho-ERK(T202/Y204)withtheIP6atpH12.Theexpression
ofphospho-ERKwasalsoapparentfollowingstimulationwithIP6
at pH 7,albeit to a smaller extent (Figure4B). Overall,our results
demonstratethatthepHoftheIP6solutiondirectlyinﬂuencedthe
IP6 actions on cellular metabolism,proliferation,and cell cycling,
as well as intracellular signaling.
DISCUSSION
Numerous publications discuss the anti-cancer properties of IP6
in in vitro and in vivo prostate cancer models (reviewed in
Vucenik and Shamsuddin, 2006). There are several cellular path-
ways affected by IP6 and the molecular machinery modulated
following IP6 treatment is being further characterized. As IP6 is
orally administered in vivo, the IP6 solution must accordingly be
edible. However, when the often-used dodecasodium IP6 salt is
reconstituted in aqueous solution, the resulting solution is at pH
12, which is not ﬁt for consumption. In this study, we questioned
whether the pH of the ingested IP6 solution could inﬂuence the
previously documented cytotoxic properties of IP6.
The results presented in this study conﬁrmed that, compared
to pH-adjusted control H2O solutions, IP6 at any pH reduced
the metabolic rate and the proliferation of hormone-refractory
PC-3 cells. However, it was the IP6 solutions at pH 5 and pH
12 that offered the most signiﬁcant inhibitory potential on the
metabolic rate of PC-3 cells and the IP6 at pH 12 that most signif-
icantly in vitro reduced cellular proliferation. Furthermore, when
we investigated the phosphorylation status of key signaling mol-
ecules described to be regulated by IP6, we observed that, again,
only the IP6 solution at pH 12 diminished the phosphorylation of
key signaling molecules. Comparatively,the IP6 at pH 5 and pH 7
didnotmodulatethephosphorylationof AKTorPDK1andhada
weakinductionof phospho-ERKcomparedtoIP6atpH12.These
results contrast with recently published data showing a signiﬁcant
FIGURE 4 | IP6 at pH 12 modulates intracellular signaling. PC-3 cells
were treated for 24h with either 2mM IP6 at pH 5, pH 7 , or pH 12 or the
corresponding volumes of H2O at pH 5, pH 7 , and pH 12. Whole-cell
extracts were prepared and Western blotting was used to probe for (A)
phospho-AKT (Ser 473), AKT, phospho-PDK1 (Ser 241) and PDK and for (B)
phospho-ERK. MG132 served as a control to induce cellular apoptosis. Blot
is representative of three independent experiments. GAPDH and actin
expression were used as a loading control. Dashed boxes signal indicate
decreased protein levels relative to water controls.
effectof IP6bufferedatpH7.4ontheproliferationof PC-3cellsas
well as on the phosphorylation status of AKT and ERK (Gu et al.,
2010). The impact of pH on the regulatory properties of IP6 on
other signaling pathways should be further assessed as our results
clearly illustrate the impact of pH on the IP6 properties.
Theintriguingresultsobservedinourstudyconcernsaccumu-
lation of sub-G1 PC-3 cells following treatment with IP6 at pH
12. Whereas short-lived and low level MOMP is observed follow-
ing treatment with both water pH 12 and IP6 pH 12, only IP6
pH 12 leads to increased cytotoxicity, acute sub-G1 cell accumu-
lation, and reduced cell growth. We must therefore conclude that
the MOMP observed in both cases is not linked with apoptosis
but may instead be an artifact induced by basic pH. The obser-
vation of sub-G1 cells only in the IP6 pH 12-treated cells (and
not at neutral or acidic pH) is nonetheless intriguing. To explain
this phenomenon, we need to consider the fact that the pI/cell
cycle assay sub-G1 peak actually measures cells in which DNA has
been fragmented and lost from the cells due to the ﬁxation proce-
dure. While DNA fragmentation occurs at late stages of apoptosis
(e.g., after 24h with MG132) it can also occur following exten-
sive DNA-damage via double-strand (DS) breaks. Note that the
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IP6 sub-G1 is maximal at 8h then progressively decreases. This
could suggest that DNA DS breaks are being induced by IP6 pH
12 early on then progressively repaired. We would further predict
that such DS breaks would occur preferentially in the G2/M phase
of the cell cycle, as the fraction of cells in this phase inversely cor-
relates with the sub-G1 peak. This idea is particularly interesting
consideringthatintheliterature,endogenousIP6normallyfound
in cells (which should be at ∼pH 7 as opposed to pH 12) has
been found to stimulate non-homologous end-joining (NHEJ)
by binding Ku70/80. It is tempting to speculate that IP6 at pH 12
inhibitsratherthatstimulatesrepairviaNHEJ,leadingtoaccumu-
lation of DS breaks in cells undergoing G2/M transition. As the
pH/ionic balance eventually re-equilibrates following IP6 pH 12
treatment (see Figures A1A,B in Appendix), NHEJ repair would
then resume leading to progressively fewer DS breaks an conse-
quently fewer sub-G1 cells over time and resumed progression
through G2/M or cell death through a non-apoptotic mechanism.
However, since we also observe decreased growth rates in cells
treated with IP6 pH 5 without accumulation of cells in sub-G1,
more experiments are needed to precisely characterize how IP6
leads to reduced cell growth rates/and death in a pH-dependent
fashion.
Onemechanismthathasbeenproposedtomediatethechemo-
preventive abilities of IP6 activity is through its role as an anti-
oxidant. The negatively charged phosphates in position 1, 2, and
3 constitute a unique (axial–equatorialaxial) conformation that
confers anti-oxidant properties to IP6 by chelating Fe3+ and pre-
venting Fe3+-catalyzed hydroxyl radical formation (Graf et al.,
1987;Hawkinsetal.,1993;Spiersetal.,1996).IP6-mediatedchela-
tion of other metals such as zinc, calcium, and magnesium has
also been proposed to play a role due to the potential role of these
divalentcationsincellproliferation(ThompsonandZhang,1991;
Jariwalla,1999;Urbanoetal.,2000).AswewouldexpectthatatpH
12,thechelatingpotentialofIP6wouldbegreaterthanatlowerpH
(because of an excess of free H+ ions), perhaps basic conditions
favor metal chelating properties of IP6. Chelating properties of
IP6, could also be expected to impact cellular processes such as
calcium-mediatedsignalingandclathrin-mediatedreceptorendo-
cytosis, which has been notably found to be inhibited by IP6 (Zi
et al.,2000).
Since the pH can change drastically as the molecule travels
through the gastro-intestinal tract,our ﬁndings have implications
forinvivouseofIP6,whichhaslargelybeenviaoralroutesthusfar.
InadditiontothefactthatmMconcentrationsof IP6arerequired
to elicit anti-cancer activity, this may argue for further evaluating
the activity of basic-pH buffered IP6 formulations by intravenous
injection. To this end, while the concentrations required for IP6-
mediatedanti-tumoractivityarecertainlyhigh,itshouldbenoted
that glucose, which is of similar chemical composition, is typi-
cally present in the blood at concentrations of ∼5mM(Lametal.,
2005). In addition, some clinically approved HDAC inhibitors,
such as sodium butyrate and valproic acid for example, are also
active in the mM range when used in vitro (Kuefer et al.,2004;Xia
et al.,2006).
In conclusion, our work demonstrates that the pH of the IP6
solution must be taken in consideration when evaluating the
anti-tumoral properties of this phytochemical. We demonstrate
signiﬁcant differences in the activity of IP6 depending on its pH
on the metabolic activity,cell proliferation,and cell death of PC-3
cells.
ACKNOWLEDGMENTS
The authors would like to thank laboratory members for helpful
discussions. We are grateful to Nathalie Delvoye for her technical
support.ThisworkissupportedbytheRenéMaloInitiativeof the
Institut du cancer de Montréal and the Fondation Sybila Hesse.
FredSaadholdstheUniversitédeMontréalChairinProstateCan-
cerResearch.PhilippeO.Gannon,IsmaëlHervéKoumakpayi,and
Jean-SimonDialloreceivesupportfromtheFondsdelaRecherche
en Santé du Québec and Deﬁ Canderel.
REFERENCES
Agarwal, C., Dhanalakshmi, S., Singh,
R. P., and Agarwal, R. (2004).
Inositol hexaphosphate inhibits
growth and induces g1 arrest and
apoptotic death of androgen-
dependent human prostate
carcinoma lncap cells. Neoplasia 6,
646–659.
Diallo, J. S., Betton, B., Parent, N.,
Peant, B., Lessard, L., Le Page, C.,
Bertrand, R., Mes-Masson, A. M.,
andSaad,F.(2008).Enhancedkilling
of androgen-independent prostate
cancer cells using inositol hexak-
isphosphate in combination with
proteasome inhibitors. Br. J. Cancer
99, 1613–1622.
Diallo, J. S., Peant, B., Lessard, L.,
Delvoye, N., Le Page, C., Mes-
Masson, A. M., and Saad, F.
(2006). An androgen-independent
androgen receptor function pro-
tects from inositol hexakisphos-
phate toxicity in the pc3/pc3(ar)
prostatecancercelllines.Prostate 66,
1245–1256.
Graf, E., Empson, K. L., and Eaton,
J. W. (1987). Phytic acid. A nat-
ural antioxidant. J. Biol. Chem. 262,
11647–11650.
Gu, M., Raina, K., Agarwal, C., and
Agarwal, R. (2010). Inositol hexa-
phosphate downregulates both con-
stitutive and ligand-induced mito-
genic and cell survival signaling,
and causes caspase-mediated apop-
totic death of human prostate carci-
noma pc-3 cells. Mol. Carcinog. 49,
1–12.
Gu, M., Roy, S., Raina, K., Agarwal,
C., and Agarwal, R. (2009). Inositol
hexaphosphate suppresses growth
and induces apoptosis in prostate
carcinoma cells in culture and nude
mouse xenograft: Pi3k-akt pathway
as potential target. Cancer Res. 69,
9465–9472.
Hawkins, P. T., Poyner, D. R., Jack-
son, T. R., Letcher, A. J., Lander, D.
A., and Irvine, R. F. (1993). Inhibi-
tion of iron-catalysed hydroxyl rad-
ical formation by inositol polyphos-
phates: a possible physiological
function for myo-inositol hexak-
isphosphate. Biochem. J. 294(Pt 3),
929–934.
Heiskanen, K. M., Bhat, M. B., Wang,
H. W., Ma, J., and Nieminen, A.
L. (1999). Mitochondrial depolar-
ization accompanies cytochrome c
release during apoptosis in pc6 cells.
J. Biol. Chem. 274, 5654–5658.
Jagadeesh,S.,and Banerjee,P. P. (2006).
Inositol hexaphosphate represses
telomerase activity and translocates
tert from the nucleus in mouse
and human prostate cancer cells via
the deactivation of akt and pkcal-
pha. Biochem. Biophys. Res. Com-
mun. 349, 1361–1367.
Jariwalla, R. J. (1999). Inositol
hexaphosphate (ip6) as an anti-
neoplastic and lipid-lowering agent.
Anticancer Res. 19, 3699–3702.
Jariwalla, R. J. (2001). Rice-bran prod-
ucts: phytonutrients with potential
applications in preventive and clin-
ical medicine. Drugs Exp. Clin. Res.
27, 17–26.
Kaufmann, S. H., Desnoyers, S., Otta-
viano, Y., Davidson, N. E., and
Poirier, G. G. (1993). Speciﬁc
proteolytic cleavage of poly(adp-
ribose) polymerase: an early marker
of chemotherapy-induced apopto-
sis. Cancer Res. 53, 3976–3985.
Kuefer, R., Hofer, M. D., Altug, V.,
Zorn, C., Genze, F., Kunzi-Rapp, K.,
Hautmann, R. E., and Gschwend,
J. E. (2004). Sodium butyrate and
tributyrin induce in vivo growth
inhibition and apoptosis in human
prostate cancer. Br. J. Cancer 90,
535–541.
Lam, T. K., Gutierrez-Juarez, R., Pocai,
A., and Rossetti, L. (2005). Regula-
tion of blood glucose by hypothal-
amic pyruvate metabolism. Science
309, 943–947.
www.frontiersin.org October 2011 | Volume 1 | Article 40 | 7Betton et al. IP6’s activity in prostate cancer
Raina, K., Rajamanickam, S., Singh,
R. P., and Agarwal, R. (2008).
Chemopreventive efﬁcacy of inosi-
tol hexaphosphate against prostate
tumor growth and progression in
tramp mice. Clin. Cancer Res. 14,
3177–3184.
Roy, S., Gu, M., Ramasamy, K., Singh,
R. P., Agarwal, C., Siriwardana, S.,
Sclafani, R. A., and Agarwal, R.
(2009). P21/cip1 and p27/kip1 are
essential molecular targets of inos-
itol hexaphosphate for its antitu-
mor efﬁcacy against prostate cancer.
Cancer Res. 69, 1166–1173.
Shamsuddin, A. M., Vucenik, I., and
Cole, K. E. (1997). Ip6: a novel anti-
cancer agent. Life Sci. 61, 343–354.
Shamsuddin, A. M., and Yang, G.
Y. (1995). Inositol hexaphosphate
inhibits growth and induces differ-
entiation of pc-3 human prostate
cancer cells. Carcinogenesis 16,
1975–1979.
Singh, R. P., Agarwal, C., and Agar-
wal, R. (2003). Inositol hexaphos-
phate inhibits growth, and induces
g1 arrest and apoptotic death of
prostate carcinoma du145 cells:
modulation of cdki-cdk-cyclin and
prb-related protein-e2f complexes.
Carcinogenesis 24, 555–563.
Singh, R. P., Sharma, G., Mallikar-
juna, G. U., Dhanalakshmi, S.,Agar-
wal, C., and Agarwal, R. (2004).
In vivo suppression of hormone-
refractory prostate cancer growth by
inositol hexaphosphate: induction
of insulin-likegrowthfactorbinding
protein-3 and inhibition of vascu-
lar endothelial growth factor. Clin
Cancer Res. 10(1 Pt 1),244–250.
Spiers, I. D., Barker, C. J., Chung,
S. K., Chang, Y. T., Freeman,
S., Gardiner, J. M., Hirst, P. H.,
Lambert, P. A., Michell, R. H.,
Poyner, D. R., Schwalbe, C. H.,
Smith, A. W., and Solomons, K. R.
(1996). Synthesis and iron bind-
ing studies of myo-inositol 1,2,3-
trisphosphate and (±)-myo-inositol
1,2-bisphosphate, and iron binding
studies of all myo-inositol tetrak-
isphosphates. Carbohydr. Res. 282,
81–99.
Thompson,L. U.,and Zhang,L. (1991).
Phytic acid and minerals: effect on
early markers of risk for mammary
and colon carcinogenesis. Carcino-
genesis 12, 2041–2045.
Urbano, G., Lopez-Jurado, M., Aranda,
P., Vidal-Valverde, C., Tenorio, E.,
and Porres, J. (2000). The role of
phytic acid in legumes: antinutri-
ent or beneﬁcial function? J. Physiol.
Biochem. 56, 283–294.
Vucenik, I., and Shamsuddin, A. M.
(2003). Cancer inhibition by inosi-
tolhexaphosphate(ip6)andinositol:
from laboratory to clinic. J. Nutr.
133(11 Suppl. 1), 3778S–3784S.
Vucenik, I., and Shamsuddin, A. M.
(2006). Protection against cancer by
dietaryip6andinositol.Nutr.Cancer
55, 109–125.
Xia, Q., Sung, J., Chowdhury,W., Chen,
C. L., Hoti, N., Shabbeer, S., Car-
ducci,M.,and Rodriguez,R. (2006).
Chronic administration of valproic
acid inhibits prostate cancer cell
growth in vitro and in vivo. Cancer
Res. 66, 7237–7244.
Zi, X., Singh, R. P., and Agarwal,
R. (2000). Impairment of erbb1
receptor and ﬂuid-phase endo-
cytosis and associated mitogenic
signaling by inositol hexaphos-
phate in human prostate carci-
nomadu145cells.Carcinogenesis 21,
2225–2235.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received:12July2011;accepted:04Octo-
ber 2011; published online: 31 October
2011.
Citation: Betton B, Gannon PO,
Koumakpayi IH, Diallo J-S, Mes-
Masson A-M and Saad F (2011)
Inﬂuence of pH on the cytotoxic activity
of inositol hexakisphosphate (IP6) in
prostate cancer. Front. Oncol. 1:40. doi:
10.3389/fonc.2011.00040
This article was submitted to Frontiers
in Molecular and Cellular Oncology, a
specialty of Frontiers in Oncology.
Copyright © 2011 Betton, Gannon,
Koumakpayi, Diallo, Mes-Masson and
Saad. This is an open-access article sub-
ject to a non-exclusive license between
the authors and Frontiers Media SA,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and other Frontiers conditions are
complied with.
Frontiers in Oncology | Molecular and Cellular Oncology October 2011 | Volume 1 | Article 40 | 8Betton et al. IP6’s activity in prostate cancer
APPENDIX
FIGUREA1 | pH variations of the culture media after IP6 or water
treatment. PC-3 cells were plated at 200,000 cells/ml in 6-well plates in a
ﬁnal volume of 3ml of medium/well.The culture media consists in RPMI
1640 complemented with 10% FCS, gentamicin (50μg/ml), and
amphotericin B (250ng/ml; Gibco, Carlsbad, CA, USA). PC-3 cells were
treated with either 2mM IP6 at pH 5, pH 7 , or pH 12 or the corresponding
volumes of H2O at pH 5, pH 7 , and pH 12. In parallel, culture media without
PC-3 cells were supplemented with similar volumes of 2mM IP6 or H2O.
The pH was measured immediately after stimulation [0h, (A)] or after 24h
(B) of treatment using a pH-meter (Corning pH meter 340, Corning, NY,
USA). Data represents average of three experiments. Errors bars represent
SD.
FIGUREA2 | LNCaP cells react differently than PC-3 cells to IP6
treatment at various pH. LNCaP cells were treated for 24h with either
2mM IP6 at pH 5, pH 7 , or pH 12 or the corresponding volumes of H2Oa t
pH 5, pH 7 , and pH 12. Whole-cell extracts were prepared and Western
blotting was used to probe for PARP , cleaved-PARP (25kDa). Blot is
representative of three independent experiments. Actin expression was
used as a loading control.
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FIGUREA3 | Phosphorylation status of several kinases in LNCaP cells
following IP6 treatment using Proteome Proﬁler membranes. LNCaP
cells were treated for 24h with either 2mM IP6 at pH 5, pH 7 , or pH 12 or
the corresponding volumes of H2O at pH 5, pH 7 , and pH 12. Whole-cell
extracts were prepared according to the manufacturer’s protocol and
hybridized to the proteome proﬁler membranes (RnD Systems).
Densitometry was performed with the Quantity One software (BioRad)
using the positive control dots (top left, bottom left, and top right corners)
in the qualitative expression ratio. Protein proﬁler membranes and
corresponding densitometry for: (A,B) pH 5, (C,D) pH 7 , (E,F) pH 12. Note
that the signal was relatively similar for the three conditions (pH 5, pH 7 ,
and pH 12) with few kinase phosphorylations detected. However, we did
observe an increase in the phosphorylation of AKT2 with the IP6 pH 12
treatment.
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TableA1 | Cell cycle distribution* following IP6 treatment.
G1 G2/M
8h 24h 48h 72h 8h 24h 48h 72h
Ctrl 53.56±2.0 55.11±2.3 58.15±4.8 56.07±3.4 25.96±0.9 25.28±4.0 24.80±4.0 27 .14±4.0
MG132 54.10±2.6 63.22±3.5 55.33±6.6 33.12±3.5 27 .76±4.3 14.15±2.6 10.70±3.2 11.62±3.8
H2O pH 5 53.18±2.2 55.06±2.3 59.76±4.6 57 .35±2.9 25.67±1.3 24.17±2.9 24.31±3.1 27 .04±2.2
H2O pH 7 53.53±1.9 54.42±2.1 58.29±4.8 55.01±3.0 25.72±1.4 25.18±3.8 23.78±4.0 28.46±3.5
H2O pH 12 53.15±2.5 52.22±2.0 56.64±5.3 55.73±2.8 25.72±1.3 26.66±3.9 24.83±3.6 27 .35±3.7
IP6 pH 5 53.95±1.8 56.71±2.2 58.13±4.0 56.89±3.1 25.80±0.9 23.94±3.1 24.33±2.7 28.43±2.1
IP6 pH 7 53.63±2.6 57 .72±2.8 58.70±5.1 56.14±2.6 26.03±0.6 24.03±3.5 25.11±3.7 26.03±2.5
IP6 pH 12 50.24±3.2 55.29±2.8 56.60±3.5 52.48±2.7 22.13±1.0 22.29±1.9 26.38±3.3 26.69±3.1
S Sub-G1
8h 24h 48h 72h 8h 24h 48h 72h
Ctrl 9.23±1.4 7 .79±0.8 6.73±0.7 7 .89±1.7 0.51±0.1 0.56±0.1 0.71±0.2 0.52±0.1
MG132 7 .86±1.1 6.00±0.6 5.19±0.9 5.82±1.0 0.59±0.1 2.37±0.7 20.28±3.4 40.13±7. 5
H2Op H5 1 1 . 0 0±2.6 8.15±0.3 6.99±0.8 8.23±1.7 0.45±0.1 0.74±0.2 0.58±0.1 0.34±0.1
H2Op H7 1 1 . 2 3±2.8 8.30±0.7 7 .10±1.6 8.44±2.1 0.41±0.1 0.78±0.1 0.65±0.1 0.37±0.0
H2Op H1 2 1 0 . 1 0±1.7 8.70±0.8 6.72±1.0 7 .24±1.8 0.71±0.2 0.59±0.2 0.73±0.1 0.35±0.0
IP6 pH 5 10.88±2.7 7 .64±1.0 8.10±1.3 8.81±2.4 0.61±0.1 1.33±0.2 0.87±0.2 0.53±0.2
IP6 pH 7 10.41±1.5 7 .92±0.9 7 .51±1.0 8.36±1.8 0.68±0.1 1.41±0.3 0.92±0.1 0.50±0.0
IP6 pH 12 8.85±1.8 8.29±1.0 7 .71±1.1 8.32±1.8 5.21±0.9 3.96±0.8 2.63±0.5 1.11 ±0.2
Results highlighted and in bold are statistically signiﬁcantly different compared to the corresponding water control.
*Cell percentage in each phase quantiﬁed by FACS following PI staining.
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